Loading
Total declarations
Company
▲ Purchases (25 ops.)
▼ Sales (0 ops.)
Latest filing published 16 Jan 2024 for Champions Oncology, INC., €5,919. Read the official filing
Filing timeline
BuySaleDaniel Newman Mendelson
Insider track record
Disclosed buys
25
Disclosed sells
0
Signal history
Closed purchases
Market purchases
25
Positive at T+90
53%
Median T+90
+6.4%
Based on 19 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +89.2%Entry US$5.81 · Close at T+365 US$10.99
- +89.2%Entry US$5.81 · Close at T+365 US$10.99
- +89.2%Entry US$5.81 · Close at T+365 US$10.99
- +89.2%Entry US$5.81 · Close at T+365 US$10.99
- +89.2%Entry US$5.81 · Close at T+365 US$10.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Daniel Newman Mendelson: trading record in brief
This profile gathers the share dealings of Daniel Newman Mendelson in Champions Oncology, Inc. Over a trading history stretching from 19 September 2023 to 12 January 2024, the count stands at 25 filings.
Every open-market trade on record is a purchase: 25 purchases worth €413k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2024, the count stands at 8 purchases and no sales.
The median purchase comes to €17k. Across 25 purchases, this insider has always bought alone, with no colleague buying within 30 days. After 19 purchases with a full 90-day history, the hit rate stands at 53% and the median 90-day move at +6.4%. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 16 January 2024: an open-market purchase of €5,919, in Champions Oncology, Inc. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Daniel Newman Mendelson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations25 total
1,000 shares@ US$6.501.4% of flowCommon StockSEC:0001628280-24-001334:0
Canonical exit: 11 Apr 2024 (T+90)
2,000 shares@ US$6.272.8% of flowCommon StockSEC:0001628280-24-001231:0
Canonical exit: 10 Apr 2024 (T+90)
2,944 shares@ US$6.314.1% of flowCommon StockSEC:0001628280-24-001118:0
Canonical exit: 9 Apr 2024 (T+90)
3,000 shares@ US$6.254.1% of flowCommon StockSEC:0001628280-24-001002:0
Canonical exit: 8 Apr 2024 (T+90)
1,000 shares@ US$6.151.4% of flowCommon StockSEC:0001628280-24-000896:0
Canonical exit: 7 Apr 2024 (T+90)
2,000 shares@ US$6.092.7% of flowCommon StockSEC:0001628280-24-000825:0
Canonical exit: 4 Apr 2024 (T+90)
3,000 shares@ US$6.124.1% of flowCommon StockSEC:0001628280-24-000820:0
Canonical exit: 3 Apr 2024 (T+90)
500 shares@ US$5.830.6% of flowCommon StockSEC:0001628280-24-000388:0
Canonical exit: 2 Apr 2024 (T+90)
2,500 shares@ US$4.922.7% of flowCommon StockSEC:0001628280-23-042662:0
Canonical exit: 20 Mar 2024 (T+90)
2,100 shares@ US$4.822.2% of flowCommon StockSEC:0001628280-23-042467:0
Canonical exit: 19 Mar 2024 (T+90)
5,000 shares@ US$4.755.3% of flowCommon StockSEC:0001628280-23-042096:0
Canonical exit: 18 Mar 2024 (T+90)
5,000 shares@ US$6.227.1% of flowCommon StockSEC:0001628280-23-034407:0
Canonical exit: 27 Dec 2023 (T+90)
4,000 shares@ US$6.165.7% of flowCommon StockSEC:0001628280-23-034409:0
Canonical exit: 28 Dec 2023 (T+90)
1,500 shares@ US$5.952.1% of flowCommon StockSEC:0001628280-23-034405:0
Canonical exit: 26 Dec 2023 (T+90)
5,000 shares@ US$6.407.3% of flowCommon StockSEC:0001628280-23-034348:0
Canonical exit: 9 Jan 2024 (T+90)
1,100 shares@ US$6.411.6% of flowCommon StockSEC:0001628280-23-034231:0
Canonical exit: 8 Jan 2024 (T+90)
1,530 shares@ US$6.482.3% of flowCommon StockSEC:0001628280-23-034119:0
Canonical exit: 4 Jan 2024 (T+90)
2,000 shares@ US$6.473.0% of flowCommon StockSEC:0001628280-23-034004:0
Canonical exit: 3 Jan 2024 (T+90)
5,000 shares@ US$6.407.4% of flowCommon StockSEC:0001628280-23-033842:0
Canonical exit: 2 Jan 2024 (T+90)
2,500 shares@ US$6.303.6% of flowCommon StockSEC:0001628280-23-033843:0
Canonical exit: 1 Jan 2024 (T+90)
5,000 shares@ US$5.656.5% of flowCommon StockSEC:0001628280-23-033077:0
Canonical exit: 25 Dec 2023 (T+90)
4,018 shares@ US$5.515.0% of flowCommon StockSEC:0001628280-23-032919:0
Canonical exit: 19 Dec 2023 (T+90)
5,000 shares@ US$5.286.0% of flowCommon StockSEC:0001628280-23-032920:0
Canonical exit: 18 Dec 2023 (T+90)
5,000 shares@ US$5.516.3% of flowCommon StockSEC:0001628280-23-032918:0
Canonical exit: 20 Dec 2023 (T+90)
3,812 shares@ US$5.504.8% of flowCommon StockSEC:0001628280-23-032917:0
Canonical exit: 21 Dec 2023 (T+90)
25 of 25 declarations
